Abstracts tagged "Biologicals"

Abstract Number: 0194 • ACR Convergence 2025
Evaluation of a Home-based Therapeutics Service: Feasibility, Patient and Caregiver Experience, and Cost
Xiaohui Xin, Andrea Low, Sow Ling Yee, Miao Miao Liu, Christina Tan, Daphne Ng and Siaw Ing Yeo, Singapore General Hospital, Singapore, Singapore
Background/Purpose: The home-based therapeutics service (HTS) by a community nurse is part of an ongoing larger initiative—Community Therapeutics Programme (CTP)—spearheaded by the Rheumatology and Immunology…
Abstract Number: 2678 • ACR Convergence 2025
The Association Between Medication Taper Duration and Time to JIA Disease Flare: A Retrospective Cohort Study
Christian-Immanuel Oliveros¹, Kelly Rouster-Stevens², Laura Johnson³ and Sampath Prahalad⁴, ¹Emory University / Children's Healthcare of Atlanta, Atlanta, GA, ²Emory University/Children's Healthcare of Atlanta, Peachtree Corners, GA, ³Emory University, Atlanta, GA, ⁴Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Once clinically inactive, many patients with oligoarticular (oligoJIA) or polyarticular JIA (polyJIA) are interested in de-escalating therapy in a safe and successful manner. Many…
Abstract Number: 2457 • ACR Convergence 2025
Maternal, Embryo-Fetal And Neonatal Outcomes Following Belimumab Exposure During Pregnancy In Patients With Systemic Lupus Erythematosus
Kenza El Ouazzani¹, Nathalie Morel¹, Delphine Beghin², Gaelle GUETTROT-IMBERT³, Noémie JOURDE-CHICHE⁴, Alban DEROUX⁵, Françoise Sarrot-Reynauld⁵, Lionel Couzi¹, Vincent Langlois⁶, Estibaliz LAZARO⁷, Pauline ORQUEVAUX⁸, Benjamin DE SAINTE MARIE⁹, Kevin Deve¹⁰, christophe Deligny¹¹, Nicole Ferreira¹², Bertrand Godeau¹³, Véronique Le Guern³, Raphaelle Meunier¹⁴, Elisabeth Pasquier¹⁵, Viviane Queyrel Moranne¹⁶, Laurent Sailler¹⁷, Cécile Saint-Pastou¹⁸, Nathalie Costedoat-Chalumeau³, Benoit Marin¹⁹ and Christophe Richez¹, ¹Bordeaux University Hospital, Bordeaux, France, ²Paris Pitié-Salpêtrière Hospital, Paris, France, ³Cochin Hospital, Paris, France, ⁴Centre de Néphrologie et Transplantation Rénale, Hôpital de la Conception, Assistance Publique-Hôpitaux de Marseille, Marseille, France., Marseille, France, ⁵Grenoble university hospital, Grenoble, France, ⁶Le Havre University Hospital, Le Havre, France, ⁷Bordeaux University Hospital, Pessac, France, ⁸Reims University Hospital, Reims, France, ⁹Timone university hospital, Marseille, France, ¹⁰Bayonne hospital, Bayonne, France, ¹¹Fort-de-France hospital, Fort-de-France, France, ¹²Tours University Hospital, Tours, France, ¹³Creteil Hospital, Paris, France, ¹⁴Libourne Hospital, Libourne, France, ¹⁵Brest University Hospital, Brest, France, ¹⁶Nice University Hospital, Nice, France, ¹⁷CHU Toulouse, Toulouse, France, ¹⁸Saint-Pierre Hospital, Saint-Pierre, France, ¹⁹Hôpital Pitié-Salpêtrière, Paris, France
Background/Purpose: Systemic lupus erythematosus (SLE) may be associated with high-risk pregnancies, especially in the presence of specific predisposing factors. While optimal disease control during pregnancy…
Abstract Number: 2343 • ACR Convergence 2025
Risk of Arrhythmias Following IL-17 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
Asim Khanfar¹, Omar Hamdan², Anil Regmi³, Mayra Goreja⁴ and Anthony Ocon⁵, ¹Rochester General Hospital, Rochester, NY, ²University of Jordan, Az-Zarqa, Jordan, ³Parkview Health, Fort Wayne, IN, ⁴Rochester General Hospital, Rochester, ⁵Rochester Regional Health, Fairport, NY
Background/Purpose: Interleukin-17 (IL-17) inhibitors, such as secukinumab and ixekizumab, are used for their anti-inflammatory effects in conditions like psoriasis and ankylosing spondylitis. IL-17 signaling has…
Abstract Number: 2022 • ACR Convergence 2025
Clinical Predictors of Macrophage Activation Syndrome and Treatment Outcomes in Adult-Onset Still’s Disease: A 24-Year Single-Center Experience
Oguzhan Omer Kizilkaya¹, Beste Acar¹, Berkay Aktas¹, Ozgur Can Kilinc¹ and serdal Ugurlu², ¹Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Adult-onset Still’s disease (AOSD) is a rare autoinflammatory disorder with heterogeneous manifestations. Its most severe complication, macrophage activation syndrome (MAS), occurs in up to…
Abstract Number: 1563 • ACR Convergence 2025
RESET-SSc: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Systemic Sclerosis
Dinesh Khanna¹, Monalisa Ghosh¹, Ankoor Shah², Sonali Bracken³, george georges⁴, Carrie Richardson⁵, Pei-Suen Tsou¹, Charles Ross⁶, Carleigh Zahn¹, Courtney Little⁷, Carl diCasoli⁷, Mikaela Raymond⁷, Adreeja GuhaRay⁷, Jenell Volkov⁷, Daniel Nunez⁷, Thomas Furmanak⁷, Jason Stadanlick⁷, Larissa Ishikawa⁷, Zachary Vorndran⁷, Alexandra Ellis⁷, Jazmean Williams⁷, Steve Flanagan⁷, Quynh Lam⁸, Domenick Braccia⁸, Fatemeh Hadi-Nezhad⁸, Raj Tummala⁸, Samik Basu⁷ and David Chang⁹, ¹University of Michigan, Ann Arbor, MI, ²Duke University, Durham, NC, ³Duke University Medical Center, Durham, NC, USA, Apex, NC, ⁴Northwestern Medicine, Evanston, IL, ⁵Northwestern University, Chicago, IL, ⁶University of Michigan, Ann Arbor, ⁷Cabaletta Bio, Philadelphia, PA, ⁸Cabaletta Bio, Philadelphia, ⁹Cabaletta Bio, Bryn Mawr, PA
Background/Purpose: The treatment goals for systemic sclerosis (SSc) are to control disease activity, limit progression of organ damage and decrease long-term morbidity and mortality. Therapies…
Abstract Number: 1449 • ACR Convergence 2025
Bimekizumab Demonstrated Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Lianne S. Gensler¹, Sofia Ramiro², Denis Poddubnyy³, Marina Magrey⁴, Irene E. van der Horst-Bruinsma⁵, Atul Deodhar⁶, Vanessa Taieb⁷, Diana Voiniciuc⁸, Natasha de Peyrecave⁹ and Martin Rudwaleit¹⁰, ¹Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Leiden University Medical Center, Bunde, Netherlands, ³Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ⁴Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH, ⁵Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ⁶Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁷UCB, Colombes, France, ⁸UCB, Slough, United Kingdom, ⁹UCB, Brussels, Belgium, ¹⁰Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ has shown sustained efficacy to Week (Wk) 52…
Abstract Number: 1344 • ACR Convergence 2025
Exploring the Factors Associated with the Discontinuation of Tofacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
yao fan fang¹, Ping-Han Tsai² and yen Fu CHEN³, ¹Chang Gung memorial hopspital, Linkou, Taipei, New Taipei, Taiwan (Republic of China), ²Chang Gung memorial hospital, linkou, Taipei, Taiwan (Republic of China), ³Chang Gung memoriial hospital linkou, taipei, Taiwan (Republic of China)
Background/Purpose: Tofacitinib is the first oral targeted synthetic disease-modify anti-rheumatic drug for patients with moderate to severe rheumatoid arthritis 1. This study aimed to identify…
Abstract Number: 1095 • ACR Convergence 2025
Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series
dellal azeddine¹, Jean-Guillaume Letarouilly², Jacques Morel³, René-Marc Flipo⁴, Valerie Devauchelle⁵, richette pascal⁶, Philippe Dieude⁷, Hubert Marotte⁸, FELTEN Renaud⁹, LATOURTE Augustin¹⁰, CHEVET Baptiste¹¹, HILLIQUIN Pascal¹², SORDET Christelle⁹, DERNIS mmanuelle¹³, WENDLING Daniel¹⁴, Arsène Mekinian¹⁵, Nathalie BALLANDRAUD¹⁶, Christophe Richez¹⁷, TOURNADRE Anne¹⁸, salmon Jean -Hugues¹⁹, SAILLOT Carine²⁰, kedra joanna²¹, nahon stephane²², LE GOFF Benoit²³, Bruno Fautrel²⁴, Francis BERENBAUM²⁵, David SAADOUN²⁶, PHAM Thao¹⁶ and SELLAM JEREMIE²⁷, ¹GHI LE RAINCY MONTFERMEIL, Montfermeil, France, ²Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, LILLE, Nord-Pas-de-Calais, France, ³CHU and University of Montpellier, Montpellier, France, ⁴Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, ⁵UBO, Brest, France, ⁶Rheumatology Department, Lariboisiere Hospital, Paris, Ile-de-France, France, ⁷Service de Rhumatologie, Hôpital Bichat APHP, Paris, Paris, Ile-de-France, France, ⁸INSERM ¹⁰⁵⁹/University of Saint-Etienne, Saint-Etienne, France, ⁹Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ¹⁰Rheumatology Department, Lariboisiere Hospital, Paris, France, ¹¹CHU BREST, brest, Bretagne, France, ¹²CH SUD FRANCILIEN, PARIS, France, ¹³chu caen, CAEN, Haute-Normandie, France, ¹⁴CHU de Besançon, Besançon, Franche-Comte, France, ¹⁵Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ¹⁶CHU MARSEILLE, marseille, Provence-Alpes-Cote d'Azur, France, ¹⁷Bordeaux University Hospital, Bordeaux, France, ¹⁸CHU CLERMONT, CLERMONT, Lorraine, France, ¹⁹CHU REIMS, REIMS, Champagne-Ardenne, France, ²⁰CHU ORLEANS, ORLEANS, Pays de la Loire, France, ²¹Pitié-Salpêtrière Hospital, Rheumatology Department, APHP, Sorbonne University,, Paris, France, ²²GHI LE RAINCY MONTFERMEIL, Montfermeil, Ile-de-France, France, ²³CHU Nantes, Nantes, France, ²⁴Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ²⁵Sorbonne University/Inserm/AP-HP/⁴Moving Biotech, Paris, France, ²⁶CHU LA PITIE SALPETRIERE, PARIS, Ile-de-France, France, ²⁷Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, /Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France., Paris, France
Background/Purpose: The use of TNFα antagonist is not recommended if the patient have a suspicion or demyelinating diseases (DD) confirmed [1]. There are a few…
Abstract Number: 0649 • ACR Convergence 2025
Belimumab Real-World Effectiveness in Chinese Patients with Systemic Lupus Erythematosus: Interim Analysis of an Ambidirectional, Observational Cohort Study (RELIABLE)
Zhuoli Zhang¹, Shengyun Liu², Min Yang³, Yasong Li⁴, Qinghong Yu⁵, Xinwang Duan⁶, Qiang Shu⁷, Qibing Xie⁸, Yanfei Chen⁹, Daming Ou¹⁰, Lan He¹¹, Hongbin Li¹², Pingting Yang¹³, Juan Li¹⁴, Terry Yan¹⁵, Xin He¹⁶, Daniel Moldaver¹⁷, Ciara O'Shea¹⁸ and Liya Fan¹⁶, ¹Peking University First Hospital, Beijing, Beijing, China (People's Republic), ²The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (People's Republic), ³Nanfang Hospital Southern Medical University, Guangzhou, China (People's Republic), ⁴Zhejiang Provincial People's Hospital, Hangzhou, China (People's Republic), ⁵Zhujiang Hospital of Southern Medical University, Zhujiang, China (People's Republic), ⁶The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ⁷Qilu Hospital of Shandong University, Jinan, China (People's Republic), ⁸West China Hospital, Sichuan University, Chengdu, China (People's Republic), ⁹The First Hospital of Lanzhou University, Lanzhou, China (People's Republic), ¹⁰The First Affiliated Hospital of University of South China, Hengyang, China (People's Republic), ¹¹The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China (People's Republic), ¹²The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), ¹³The First Hospital of China Medical University, Shenyang, China (People's Republic), ¹⁴The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), ¹⁵Medical Affairs, GSK, Shanghai, China (People's Republic), ¹⁶VEO, GSK, Shanghai, China (People's Republic), ¹⁷GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ¹⁸Global Medical Affairs, GSK, Dublin, Ireland
Background/Purpose: Belimumab, a B-cell modulator monoclonal antibody that selectively inhibits BLyS and reduces autoreactive B-cells that drive lupus disease activity, has consistently demonstrated improved efficacy…
Abstract Number: 0803 • ACR Convergence 2025
Improved Efficacy and Safety Outcomes in Patients with SLE Treated with Belimumab (BEL) Versus Immunosuppressants (IS), in Addition to Antimalarials (AM) and Glucocorticoids (GC): A Post Hoc Summary of Five Phase 3 Trials
Mariele Gatto¹, Karen H. Costenbader², Andreas Schwarting³, Julia Harris⁴, Ciara O'Shea⁵, Roger A. Levy⁶ and Andrea Doria⁷, ¹Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, Mauriziano Hospital, Turin, Italy, ²Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ³Johannes Gutenberg University Mainz, University Medical Centre, Mainz, Germany, ⁴GSK, Biostatistics, London, United Kingdom, ⁵Global Medical Affairs, GSK, Dublin, Ireland, ⁶GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁷University of Padova, Padova, Italy
Background/Purpose: Chronic GC and IS use increases damage accrual and mortality. The 2023 EULAR SLE recommendations support initiation of biologics such as BEL, a human…
Abstract Number: 0484 • ACR Convergence 2025
Comparable Efficacy of FK-Tocilizumab and Reference Tocilizumab in Rheumatoid Arthritis Patients With and Without Prior Biologic Exposure
Ernest Choy¹, Marco Gattorno², Kamila Klama³, Andras Illes⁴, Peter Baker⁵, Maria Romanova Michailidi⁶ and Anna Zubrzycka-Sienkiewicz⁷, ¹Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ²IRCCS G. Gaslini, Genova, Genoa, Italy, ³Solumed Clinical Research Center, Poznan, Poland, ⁴Fresenius Kabi SwissBioSim, Eysin, Switzerland, ⁵Fresenius Kabi Biopharma, Eysins, Switzerland, ⁶University of Geneva, Eysins, Switzerland, ⁷Reumatika - Centrum Reumatologii, Warszawa, Poland
Background/Purpose: Biosimilars offer comparable efficacy and safety to their originators, thereby improving patient access to affordable treatments. FK-Tocilizumab (FK-toci) is the first tocilizumab biosimilar approved…
Abstract Number: 0180 • ACR Convergence 2025
Digital Transformation in IMID Care: Results from the Implementation of IMIDOC
JOSE INIESTA-CHAMORRO¹, Marta Novella-Navarro², Diego Benavent³, HELENA BORREL-PAÑOS⁴, Xabier Michelena Vegas⁵, Javier Bachiller⁶, Verónica García García⁷, ESTHER ESPARTAL⁴, LETICIA LOJO-OLIVEIRA⁸, Enrique Calvo-Aranda⁹, José Rodríguez gago¹⁰, Gema Bonilla¹¹, Irene Monjo Henry², Victoria Navarro-Compan¹², Jaime Arroyo¹⁰, Eugenio de Miguel², Mariana Díaz-Almirón¹³, cARMEN ALEGRE¹⁰, ENRIQUE J GÓMEZ¹⁴ and Chamaida Plasencia-Rodríguez², ¹¹Biomedical Engineering and Telemedicine Centre, ETSIT, Center for Biomedical Technology, Universidad Politéctica de Madrid, TELEMEDICINE, MADRID, ²Hospital Universitario La Paz, Madrid, Spain, ³Hospital Universitari de Bellvitge, Madrid, Spain, ⁴⁴HOSPITAL UNIVERSITARIO VALL D´HEBRON, RHEUMATOLOGY, BARCELONA, Spain,, BARCELONA, ⁵Hospital Universitari Vall Hebron, Barcelona, Spain, ⁶Hospital Ramon y Cajal, Madrid, Madrid, Spain, ⁷Ramón y Cajal University Hospital, MADRID, Spain, ⁸Hospital Universitario Infanta Leonor, Madrid, Spain, ⁹Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, madrid, ¹⁰Hospital Universitario La Paz, MADRID, ¹¹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ¹²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ¹³LIMA, Advanced Medical Informatics Lab, La Paz Research Institute, IdiPAZ, Madrid, Spain, ¹⁴¹Biomedical Engineering and Telemedicine Centre, ETSIT, Center for Biomedical Technology, Universidad Politéctica de Madrid, TELEMEDICINE, MADRID, Spain,, MADRID
Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA) are immune-mediated inflammatory diseases (IMIDs) characterized by joint and spinal inflammation, leading to functional impairment. Their management requires…
Abstract Number: 2669 • ACR Convergence 2025
RESET-Myositis: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Idiopathic Inflammatory Myopathies
Erin Wilfong¹, Tahseen Mozaffar², Elie Naddaf³, Nizar Chahin⁴, Huifang Lu⁵, Iazsmin Bauer Ventura⁶, Courtney Little⁷, Carl diCasoli⁷, Claire Miller⁸, Jenell Volkov⁷, Daniel Nunez⁷, Thomas Furmanak⁷, Jason Stadanlick⁷, Larissa Ishikawa⁷, Zachary Vorndran⁷, Alexandra Ellis⁷, Jazmean Williams⁷, Steve Flanagan⁷, Quynh Lam⁸, Fatemeh Hadi-Nezhad⁸, Raj Tummala⁸, Samik Basu⁷ and David Chang⁹, ¹Vanderbilt University Medical Center, Nashville, TN, USA, Nashville, TN, ²University of California, irvine, Orange, CA, ³Mayo Clinic, Rochester, MN, ⁴Oregon Health & Science University, Portland, ⁵UT MD Anderson Cancer Center, Houston, TX, ⁶University of Chicago, Chicago, IL, ⁷Cabaletta Bio, Philadelphia, PA, ⁸Cabaletta Bio, Philadelphia, ⁹Cabaletta Bio, Bryn Mawr, PA
Background/Purpose: The goals of treatment for idiopathic inflammatory myopathy (IIM) are to eliminate or reduce inflammation, restore muscle performance, reduce morbidity, and improve a patient’s…
Abstract Number: 2456 • ACR Convergence 2025
Predictors of Real-World Remission in Patients with SLE Initiating Belimumab in the USA
Aarat M Patel¹, Renee L. Gennarelli², Temitope Bello², Ali Bonakdar² and Karen Worley³, ¹GSK, US Medical Affairs, Durham, NC, ²Cencora, Real-World Evidence, Conshohocken, PA, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA
Background/Purpose: The Definition Of Remission in SLE (DORIS) criteria were developed to align SLE remission definitions.1,2 Post hoc analyses of clinical trial data demonstrated that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].